anti-GPC3 CAR T-cell therapy dnTGF-betaRII (AstraZeneca)

N/A

Report date: 2025/01/26 16:28:45

Base Information

Drug Nameanti-GPC3 CAR T-cell therapy dnTGF-betaRII (AstraZeneca)
Drug Alias NameGlypican-3 targeting chimeric antigen receptors T cell therapy (AstraZeneca)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Pharmaceuticals Lp
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceuticals Lp
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A